Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

2 Survival Rates for Gastrointestinal Carcinoid Tumors. ACS website ... 5 Population Estimate: Unresectable, Locally Advanced or Metastatic Extra-Pancreatic NET. June 2024 (internal data on ...

This article looks at seven possible causes of facial flushing, both benign (harmless) and malignant ... Carcinoid syndrome is a rare condition typically affecting people with advanced carcinoid ...

Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of ...

It is indicated for those with previously treated, locally advanced or metastatic, well-differentiated ... M.D., clinical director of the Gastrointestinal Cancer Center and director of the Program in ...

Background: Primary malignant tumors of the trachea are rare ... (2.5%), adenosquamous carcinoma in 3 patients (3.8%), cystadenocarcinoma in 1 patient (1.3%), carcinoid carcinoma in 1 patient (1.3%), ...

A University of Manitoba-led study has successfully eliminated breast-cancer-derived brain tumors in mice, using a drug to ...

Brain metastases become more prevalent with each line of therapy in metastatic breast cancer and are more common in patients with certain cancer subtypes, new research shows.